The dependence of tumor cells on multiple oncogenic pathways and poor tolerability could contribute to the failure of monotherapy with pan-PI3K and mTOR inhibitors in solid cancers, including CRC [130]. This evidence concerns the gene PIK3CB and neoplasm.